| 000 | 01870 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250518051202.0 | ||
| 264 | 0 | _c20200615 | |
| 008 | 202006s 0 0 eng d | ||
| 022 | _a1558-8238 | ||
| 024 | 7 |
_a10.1172/JCI127613 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChatterjee, Payel | |
| 245 | 0 | 0 |
_aSupraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage. _h[electronic resource] |
| 260 |
_bThe Journal of clinical investigation _c07 2019 |
||
| 300 |
_a4245-4260 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S. | ||
| 650 | 0 | 4 |
_aAndrogens _xpharmacology |
| 650 | 0 | 4 |
_aBRCA2 Protein _xdeficiency |
| 650 | 0 | 4 |
_aCellular Senescence _xdrug effects |
| 650 | 0 | 4 | _aDNA Damage |
| 650 | 0 | 4 |
_aG1 Phase Cell Cycle Checkpoints _xdrug effects |
| 650 | 0 | 4 | _aGene Amplification |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aPC-3 Cells |
| 650 | 0 | 4 |
_aPoly(ADP-ribose) Polymerases _xgenetics |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aReceptors, Androgen _xgenetics |
| 650 | 0 | 4 |
_aResting Phase, Cell Cycle _xdrug effects |
| 700 | 1 | _aSchweizer, Michael T | |
| 700 | 1 | _aLucas, Jared M | |
| 700 | 1 | _aColeman, Ilsa | |
| 700 | 1 | _aNyquist, Michael D | |
| 700 | 1 | _aFrank, Sander B | |
| 700 | 1 | _aTharakan, Robin | |
| 700 | 1 | _aMostaghel, Elahe | |
| 700 | 1 | _aLuo, Jun | |
| 700 | 1 | _aPritchard, Colin C | |
| 700 | 1 | _aLam, Hung-Ming | |
| 700 | 1 | _aCorey, Eva | |
| 700 | 1 | _aAntonarakis, Emmanuel S | |
| 700 | 1 | _aDenmeade, Samuel R | |
| 700 | 1 | _aNelson, Peter S | |
| 773 | 0 |
_tThe Journal of clinical investigation _gvol. 129 _gno. 10 _gp. 4245-4260 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1172/JCI127613 _zAvailable from publisher's website |
| 999 |
_c29906092 _d29906092 |
||